Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2008-05-20
2008-05-20
Navarro, Mark (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S001410, C424S001570, C424S001690, C424S130100, C424S139100, C424S143100, C424S156100, C424S184100, C424S193100, C424S278100, C424S529000, C435S325000, C435S344000, C436S063000, C436S066000, C530S388220
Reexamination Certificate
active
10956250
ABSTRACT:
Methods and compositions are provided for the diagnosis and treatment of iron misregulation diseases, including HFE polypeptides, agonists, and antagonists, and transferrin receptor agonists and antagonists.
REFERENCES:
patent: 4399216 (1983-08-01), Axel et al.
patent: 4434156 (1984-02-01), Trowbridge
patent: 4511503 (1985-04-01), Olson et al.
patent: 4666927 (1987-05-01), Hider et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4711845 (1987-12-01), Gelfand et al.
patent: 4912118 (1990-03-01), Hider et al.
patent: 5075469 (1991-12-01), Chevion
patent: 5104865 (1992-04-01), Hider et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5185368 (1993-02-01), Peter et al.
patent: 5256676 (1993-10-01), Hider et al.
patent: 5328992 (1994-07-01), Peter et al.
patent: 5385918 (1995-01-01), Connell et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5420008 (1995-05-01), Nishida et al.
patent: 5424057 (1995-06-01), Peter et al.
patent: 5582979 (1996-12-01), Weber
patent: 5705343 (1998-01-01), Drayna et al.
patent: 5712098 (1998-01-01), Tsuchihashi et al.
patent: 5719125 (1998-02-01), Suzuki et al.
patent: 5753438 (1998-05-01), Drayna et al.
patent: 5872237 (1999-02-01), Feder et al.
patent: 6025130 (2000-02-01), Thomas et al.
patent: 6140305 (2000-10-01), Thomas et al.
patent: 6228594 (2001-05-01), Thomas et al.
patent: 6284732 (2001-09-01), Feder et al.
patent: 6391852 (2002-05-01), Feder et al.
patent: 2115221 (1994-08-01), None
patent: 2115222 (1994-08-01), None
patent: 2115224 (1994-08-01), None
patent: 208 609 (1984-04-01), None
patent: 4 327 226 (1995-02-01), None
patent: 0 315 434 (1989-05-01), None
patent: 0 346 281 (1989-12-01), None
patent: 97910741 (2003-06-01), None
patent: 2 293 269 (1996-03-01), None
patent: WO 94/01463 (1994-01-01), None
patent: WO 94/04186 (1994-03-01), None
patent: WO 94/11367 (1994-05-01), None
patent: WO 94/21243 (1994-09-01), None
patent: WO 95/16663 (1995-06-01), None
patent: WO 96/06583 (1996-03-01), None
patent: WO 96/17870 (1996-06-01), None
patent: WO 96/35802 (1996-11-01), None
patent: WO 97/38137 (1997-10-01), None
patent: WO 98/56814 (1998-12-01), None
Harrison et al. 2003. J. of Hepatology. vol. 38:S14-S23.
Hemochromatosis-Genetics Home Reference. http://ghr.nlm.nih.giv/condition+hemochromatosis□□.
Beutler, E. et al., “Mutation Analysis in Hereditary Hemochromatosis”Blood Cells, Molecules, and Diseases(1996), 22(16): 187-194.
Gasparini, et al, “Where does the gene for Hemochromatosis lie in relation to HLA-A”,Hepatology(1994), 19: 1050-1056.
VogeL, et al., “Human Chromosomes,” Springer-Verlag (1992) pp. 18-81.
Seese, et al., “Localization of the Hemochromatosis Disease Gene : Linkage Disequilibrium Analysis using an American Patient Collection,”Blood Cells, Molecules&Diseases(1996) 22:36-46.
Gandon et al., “Linkage Disequilibrium and Extended Haplotypes in the HLA-A to D6S105 Region: Implications for Mapping the Hemochromatosis Gene (HFE),”J. Hum. Genet.(1996) 97(1):103-13.
Adams, M.D., et al., “Complementary DNA Sequencing: Expressed Sequence Tags and Human Genome Project,” Science (1991) 252:1651-1656 (National Institutes of Health).
Amadou, C., et al., “Localization of New Genes and Markers to the Distal Part of the Human Major Histocompatibility Complex(MHC)Region and Comparison With the Mouse: New Insights Into the Evolution of Mammalian Genomes,” Genomics (1995) 26:9-20.
Anderson, J.R., et al., “Precipitating Autoantibodies in Sjögren's Disease,” Lancet (1961) 2:456-460 (Glasgow Univ.).
Bacon, B.R., “Causes of Iron Overload,” N. Engl. J. Med. (1992) 326(2):126-127 (St. Louis Univ. School of Medicine).
Balan, V., et al., “Screening for Hemochromatosis: A Cost-Effectiveness Study Based on 12,258 Patients,” Gastroenterology (1994) 107:453-459.
Barton, J.C., et al., “Blood Lead Concentrations in Hereditary Hemochromatosis,” J. Lab. Clin. Med. (1994) 124(2):193-198.
Barton, J.C., et al., “Hemochromatosis: The Genetic Disorder of the Twenty-First Century,” Nature Medicine (1996) 2(4):394-395 (Brookwood Medical Center).
Beaucage, S.L., et al., “Deoxynucleoside Phosphoramidites-A New Class of Key Intermediates for Deoxypolynucleotide Synthesis,” Tetrahedron Letters (1981) 22(20):1859-1862.
Beggs, J.D., “Transformation of Yeast by a Replicating Hybrid Plasmid,” Nature (1978) 275:104-109.
Benton, W.D., et al., “Screening λgt Recombinant Clones by Hybridization to Single Plaques in situ,” Science (1977) 196:180-182 (National Institutes of Health).
Beutler, E., et al., “A Strategy for Cloning the Hereditary Hemochromatosis Gene,” Blood Cells, Molecules, and Diseases (1995) 21(21):207-216.
Boretto, J., et al., “Anonymous Markers Located on Chromosome 6 in the HLA-A Class I Region: Allelic Distribution in Genetic Haemochromatosis,” Hum. Genet. (1992) 89:33-36 (Institut National de la Santa et de la Recherche Medicale).
Botstein, D., et al., “Sterile Host Yeasts(SHY):A Eukaryotic System of Biological Containment for Recombinant DNA Experiments,” Gene (1979) 8:17-24 (American Cancer Society).
Broach, J.R., et al., “Transformation in Yeast: Development of a Hybrid Cloning Vector and Isolation of the CANI Gene,” Gene (1979) 8:121-133 (National Institutes of Health).
Calandro, L.M., et al., “Characterization of a Recombinant That Locates the Hereditary Hemochromatosis Gene Telomeric to HLA-F,” Hum. Genet. (1995) 96:339-342 (Kaiser Foundation Research Institute).
Camaschella, C., et al., “Hereditary Hemochromatosis: Recent Advances in Molecular Genetics and Clinical Management,” Haematologica (1997) 82:77-84 (BioMed).
Campbell, A.M., “Monoclonal Antibody Technology,” Elsevier Science Publishers (1985) Chapter 1 pp. 1-32 (ISBN 0-444-80592-3).
Capecchi, M.R., “Altering the Genome by Homologous Recombination,” Science (1989) 244:1288-1292 (Univ. of Utah Medical Center).
Cartwright, G.E., et al., “Inheritance of Hemochromatosis: Linkage to HLA,” Trans. Assoc. Am. Phys. (1978) 91:273-281 (National Institutes of Health).
Chen, X., et al., “Template-Directed Dye-Terminator Incorporation(TDI)Assay: A Homogeneous DNA Diagnostic Method Based on Fluorescence Resonance Energy Transfer,” Nucl. Acids Res. (1997) 25(2):347-353 (U.S. Dept. of Energy).
Chong, S.S., et al., “Molecular Cloning of the cDNA Encoding a Human Renal Sodium Phosphate Transport Protein and its Assignment to Chromosome 6p21.3-p23,” Genomics (1993) 18:355-359.
Church, D.M., et al., “Isolation of Genes From Complex Sources of Mammalian Genomic DNA Using Exon Amplificaiton,” Nature Genetics (1994) 6:98-105 (National Institutes of Health).
Clark, G., et al., “Characterization of a Soluble Cytoplasmic Antigen Reactive With Sera From Patients With Systemic Lupus Erythmatosus,” J. Immunol. (1969) 102(1):117-122 (Univ. of New York Dept. of Medicine).
Cornall, R.J., et al., “The Generation of a Library of PCR-Analyzed Microsatellite Variants for Genetic Mapping of the Mouse Genome,” Genomics (1991) 10:874-881.
Crawford, D.H.G., et al., “Evidence That the Ancestral Haplotype in Australian Hemochromatosis Patients May be Associated With a Common Mutation in the Gene,” Am. J. Hum. Genet. (1995) 57:362-367.
Crystal, R.G., “Gene Therapy Strategies for Pulmonary Disease,” Am. J. Med. (1992) 92(6A):6A-44S-6A-52S (National Institutes of Health).
Darnell, J., “Tools of Molecular Cell Biology: Molecular Technology,” Scientific American Books (1986) pp. 227-229 (Rockefeller Univ.).
Dausset, J., et al., “Centre d'Etude du Polymorphisme Humain(CEPH):Collaborative Genetic Mapping of the Human Genome,” Genomics (1990) 6:575-577.
de Sousa, M., et al., “Iron Overload in β2-Microglobulin-Deficient Mice,” Imm
Feder John N.
Schatzman Randall C.
Tsuchihashi Zenta
Bio-Rad Laboratories, Inc.
Hines J.
Jones Day
Navarro Mark
LandOfFree
Methods and compositions for diagnosis and treatment of iron... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for diagnosis and treatment of iron..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for diagnosis and treatment of iron... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3929641